{"id":"NCT01958164","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion","officialTitle":"A Multicenter, Open-label, Randomised, Clinical Trial to Compare the Efficacy and Safety of Actilyse 2 mg/ 2 ml Versus Saline Solution in Restoring Function of an Occluded Central Venous Access Device","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2013-10-09","resultsPosted":"2015-05-01","lastUpdate":"2015-05-01"},"enrollment":16,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Catheter Obstruction","Vascular Access Devices"],"interventions":[{"type":"DRUG","name":"Actilyse","otherNames":[]},{"type":"DRUG","name":"Saline solution","otherNames":[]},{"type":"DRUG","name":"Actilyse","otherNames":[]},{"type":"DRUG","name":"Actilyse","otherNames":[]}],"arms":[{"label":"Actilyse 2 mg/2 ml","type":"EXPERIMENTAL"},{"label":"Saline solution (NaCl 0.9%)","type":"SHAM_COMPARATOR"}],"summary":"This is a multicentre, open-label, randomised, phase III study designed to evaluate the efficacy and safety of Actilyse 2 mg/2 ml in the restoration of function of CVAD","primaryOutcome":{"measure":"Proportion of Patients With Restored CVAD Function at 120 Min After Administration of the First Dose of Study Medication","timeFrame":"120 minutes after first drug administration","effectByArm":[{"arm":"Actilyse","deltaMin":83.3,"sd":null},{"arm":"Saline Solution + Actilyse","deltaMin":10,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":5,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Arterial hypertension"]}}